Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications

Rhea-AI Summary

Polyrizon (Nasdaq: PLRZ) signed a non-binding MOU to acquire up to a 20% stake in Colugo Systems, an Israeli developer of advanced eVTOL drones, for up to US $6,000,000 payable in cash or Polyrizon shares.

The MOU requires a definitive agreement, corporate approvals, resolution of rights of first refusal or co-sale, and is expected to close promptly (within 7 days after conditions). The MOU expires on September 30, 2026 if not closed earlier.

Positive

• Acquisition target: up to 20% stake in Colugo
• Deal value: up to $6,000,000 consideration
• Colugo has field-proven defense and first-responder customers

Negative

• MOU is non-binding, so transaction is not guaranteed
• Consideration may be paid with Polyrizon shares, implying potential dilution
• Closing contingent on approvals and waiver/exercise of ROFR/co-sale rights

News Market Reaction – PLRZ

-5.03%

7 alerts

-5.03% News Effect

+5.8% Peak Tracked

-9.5% Trough Tracked

-$1M Valuation Impact

$23.10M Market Cap

0.5x Rel. Volume

On the day this news was published, PLRZ declined 5.03%, reflecting a notable negative market reaction. Argus tracked a peak move of +5.8% during that session. Argus tracked a trough of -9.5% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $23.10M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Colugo stake size: Up to 20% Colugo purchase price cap: $6,000,000 Expected closing window: 7 days +5 more

8 metrics

Colugo stake size Up to 20% Outstanding share capital on a fully-diluted basis per MOU

Colugo purchase price cap $6,000,000 Aggregate consideration in cash or Polyrizon shares for Colugo stake

Expected closing window 7 days Post-satisfaction of MOU conditions for Colugo transaction

MOU termination date September 30, 2026 MOU ends if transaction not closed by this date

Colugo patent base 5 patents Adaptive Wing Technology (AWT) patents underpinning ARC aircraft range

Shelf registration size $50,000,000 Form F-3 shelf capacity for future offerings

Planned Arrow stake 51% Intended controlling interest in Arrow Aviation under prior MOU

Arrow Aviation revenue $19M Unaudited annual revenue of Arrow Aviation cited in prior deal

Market Reality Check

Price: $12.00 Vol: Volume 19,137 is 40% belo...

low vol

$12.00 Last Close

Volume Volume 19,137 is 40% below the 20-day average of 31,938, suggesting muted trading interest pre-announcement. low

Technical Shares trade above the 200-day MA at $8.5, with the current price at $14.3, reflecting a recovery from prior lows.

Peers on Argus

Biotech peers show mixed moves, with several (e.g., TTNP, ADTX, SXTP) down while...

1 Down

Biotech peers show mixed moves, with several (e.g., TTNP, ADTX, SXTP) down while ENSC is modestly up. No broad Healthcare/Biotech move clearly aligns with PLRZ’s activity.

Previous Acquisition Reports

1 past event · Latest: Feb 04 (Positive)

Same Type Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Feb 04	Acquisition MOU signed	Positive	-15.2%	Non-binding MOU to buy 51% of Arrow Aviation, entering private aviation.

Pattern Detected

Previous acquisition-related news (Arrow Aviation MOU) had a -15.16% one-day move despite an expansion-focused announcement, suggesting past market skepticism toward diversification deals.

Recent Company History

Recent history for Polyrizon shows a growing focus on acquisitions adjacent to its core intranasal biotech platform. On Feb 4, 2026, the company signed a non-binding MOU to acquire a 51% stake in Arrow Aviation, a private aviation company with ≈$19M revenue and ≈$3M adjusted EBITDA, which saw shares fall 15.16% over 24 hours. Today’s Colugo stake MOU continues this strategy of entering aviation-related markets.

Historical Comparison

-15.2% avg move · In the past, Polyrizon’s only tagged acquisition MOU (Arrow Aviation) saw a -15.16% one-day reaction...

acquisition

-15.2%

Average Historical Move acquisition

In the past, Polyrizon’s only tagged acquisition MOU (Arrow Aviation) saw a -15.16% one-day reaction. The current Colugo minority-stake MOU echoes this diversification theme into aviation-linked businesses.

Acquisition activity has evolved from a planned 51% control stake in Arrow Aviation to an intended 20% minority position in Colugo’s eVTOL drone business, extending Polyrizon’s reach into aviation and air mobility.

Regulatory & Risk Context

Active S-3 Shelf · $50,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-07

$50,000,000 registered capacity

Polyrizon filed a Form F-3 shelf on Nov 7, 2025 to offer up to $50,000,000 in securities, including ordinary shares, warrants and units. The shelf is not yet effective and shows 0 takedowns so far, but once effective it would provide pre-cleared capacity for future capital raises that could fund transactions like the Colugo stake or other corporate purposes.

Market Pulse Summary

The stock moved -5.0% in the session following this news. A negative reaction despite the Colugo MOU...

Analysis

The stock moved -5.0% in the session following this news. A negative reaction despite the Colugo MOU would fit prior patterns where diversification was not rewarded. The Arrow Aviation MOU saw shares move -15.16% in 24 hours, even with ≈$19M revenue and ≈$3M EBITDA at the target. Investors may focus on the up to $6,000,000 outlay and the unused $50,000,000 shelf as potential overhangs, especially if funding needs increase.

Key Terms

memorandum of understanding, eVTOL, urban air mobility, vtol, +2 more

6 terms

memorandum of understanding financial

"today announced the signing of a non-binding Memorandum of Understanding (“MOU”)"

A memorandum of understanding (MOU) is a formal agreement between two or more parties that outlines their shared intentions and plans to work together. It acts like a handshake in writing, clarifying each side’s roles and expectations before any official contract is signed. For investors, an MOU signals that parties are serious about collaboration, which can influence future business opportunities and potential growth.

eVTOL technical

"developer of advanced electric Vertical Take-Off and Landing (eVTOL) drone systems"

eVTOL stands for "electric vertical takeoff and landing" aircraft, which are small, electric-powered vehicles capable of taking off and landing vertically like a helicopter. They are designed to provide quick, on-demand transportation within cities or between locations, potentially transforming urban mobility. For investors, eVTOLs represent a growing segment of innovative transportation technology with potential for significant market impact and future growth.

urban air mobility technical

"shaping aviation in the emerging Urban Air Mobility (UAM) market"

Urban air mobility is the emerging system of using small aircraft—often electric vertical takeoff and landing vehicles and delivery drones—to move people and goods around cities. Think of it as adding a new layer of roads in the sky that could cut travel time and congestion, but it matters to investors because success depends on technology, safety, regulation, airspace rules and new infrastructure, all of which affect costs, adoption and revenue potential.

vtol technical

"wind endurance in a vertical take-off and landing (VTOL) vehicle– a one-of-a-kind package"

VTOL stands for vertical take-off and landing and describes aircraft that can lift off and land straight up and down instead of needing a runway, like a helicopter combined with an airplane. Investors care because VTOL designs open new markets for short-range transport, air taxis, cargo delivery and defense applications, and they bring specific technical, regulatory and manufacturing risks and costs that can affect a company’s revenue potential and timeline for profits.

fully-diluted financial

"approximately 20% of the outstanding share capital of Colugo on a fully-diluted basis"

Fully-diluted means the total number of shares that would exist if every outstanding option, warrant, convertible security and any other promise of future shares were exercised or converted. Investors use the fully-diluted share count to see the largest possible pool of shares that can dilute earnings, ownership percentages and per-share values — like knowing the size of a cake if you include every promised slice before dividing it.

right of first refusal financial

"waiver or exercise of any right of first refusal or co-Sale rights of certain Colugo shareholders"

A right of first refusal gives an existing shareholder or party the chance to buy an asset or shares before the owner can sell them to someone else. Think of it like being offered the first option to buy a house when the owner decides to sell; it matters to investors because it can limit who can acquire a stake, slow or block transactions, and affect the price and liquidity of an investment by restricting open-market sales or new buyers.

AI-generated analysis. Not financial advice.

The Company signed a non-binding MOU with shareholders of Colugo. Colugo’s customer include the Israel Defense Forces, national first responders organizations and commercial companies

Raanana, Israel, March 24, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced the signing of a non-binding Memorandum of Understanding (“MOU”) with shareholders of Colugo Systems Ltd. (“Colugo”), an innovative Israeli developer of advanced electric Vertical Take-Off and Landing (eVTOL) drone systems, for the acquisition of up to 20% stake in Colugo.

Established in 2016, Colugo designs and manufactures innovative aircraft that are designed to drive advancements in shaping aviation in the emerging Urban Air Mobility (UAM) market. Based on five unique patents in Adaptive Wing Technology (AWT), the company’s ARC aircraft range combine long-distance flight, prolonged hovering capabilities, and ultimate wind endurance in a vertical take-off and landing (VTOL) vehicle– a one-of-a-kind package that is unparalleled in the market. Colugo has significant field-proven success in providing air support and military-grade services for the defense, homeland security and disaster management sectors, including to the Israel Defense Forces, national first responders organizations and commercial companies.

Under the terms of the MOU, two shareholders will sell to Polyrizon approximately 20% of the outstanding share capital of Colugo on a fully-diluted basis. The aggregate purchase price for the Colugo shares is up to US $6,000,000, either in cash or through the issuance of Polyrizon shares, as shall be mutually agreed upon in the definitive agreement. Polyrizon’s share price will be determined at the signing of the definitive agreement.

The closing of Polyrizion acquisition of the Colugo shares is expected to occur promptly (and in any event within 7 days) following satisfaction of the conditions set forth in the MOU, including execution of a definitive agreement, required corporate approvals of both companies, and waiver or exercise of any right of first refusal or co-Sale rights of certain Colugo shareholders. The MOU will terminates upon the earlier of written notice of termination by either party or September 30, 2026, if the transaction has not closed by such date.

About Polyrizon

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the final terms and signing of definitive agreements with shareholders of Colugo Systems Ltd., the timing and completion of the acquisition, and the satisfaction of closing conditions related to the acquisition. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.

Contacts:

Michal Efraty
Investor Relations
IR@polyrizon-biotech.com

FAQ

What stake will Polyrizon (PLRZ) acquire in Colugo under the March 24, 2026 MOU?

Polyrizon intends to acquire up to a 20% stake in Colugo on a fully diluted basis. According to the company, two shareholders agreed to sell approximately 20% of Colugo subject to a definitive agreement and closing conditions.

How much will Polyrizon (PLRZ) pay for the Colugo stake and in what forms?

The aggregate purchase price is up to US $6,000,000, payable in cash or Polyrizon shares. According to the company, the exact mix and Polyrizon share price will be determined at signing of the definitive agreement.

What are the key closing conditions for PLRZ's proposed Colugo purchase and expected timing?

Closing requires a definitive agreement, corporate approvals, and waiver or exercise of ROFR/co-sale rights. According to the company, the acquisition is expected to close promptly and within 7 days after satisfying those conditions, subject to the MOU timeline.

Does the March 24, 2026 MOU guarantee Polyrizon's acquisition of Colugo shares?

No, the MOU is non-binding and does not guarantee closing. According to the company, the MOU will terminate on written notice or on September 30, 2026 if the transaction has not closed by that date.

What strategic benefits does the Colugo investment provide for Polyrizon (PLRZ)?

The investment provides exposure to Colugo's eVTOL technology and defense/commercial customers. According to the company, Colugo holds five patents in Adaptive Wing Technology and serves defense, first responders, and commercial clients.